First randomized clinical trial of SBRT reports primary outcome

In the first trial ever to randomly assign patients to extreme hypofractionation, primary radiation therapy delivered in just seven treatments had the same effectiveness and safety as 39 treatments. … READ MORE …

RALP vs. open surgery: “similar functional outcomes at 12 weeks”

Back in July we reported the initial publication on line of the results of a randomized Phase III trial by Yaxley et al. that compared the initial outcomes of open radical retropubic prostatectomy to robot-assisted laparoscopic prostatectomy (RALP). This paper has now been published by The Lancet along with two sets of editorial commentary. … READ MORE …

First data from a RTC of proton beam radiation vs. conventional radiation therapy

When you go to large meetings with thousands of presentations, you miss things. And here’s one that a lot of people seem to have missed — your sitemaster included. … READ MORE …

Has TOAD resolved a real and long-standing question?

So TOAD stands for “Timing of Androgen Deprivation” and refers to a randomized, multi-center, Phase III trial carried out in Australia, New Zealand, and Canada between September 3, 2004, and July 13, 2012. … READ MORE …

Reduction in prostate size prior to permanent seed prostate brachytherapy

Data from a randomized clinical trial have shown that there is more than one way to reduce the size of a man’s prostate (if such cytoreduction is needed) prior to treatment with permanent, radioactive pellets (permanent, low-dose brachytherapy) for localized prostate cancer. … READ MORE …

Some data from a randomized, prospective trial of surgery vs. radiation therapy

We should emphasize immediately that the available data from the trial discussed below are not exactly compelling. For whatever reasons, the trial didn’t enroll enough patients to allow any conclusions about the relative effectiveness to the two forms of treatment. … READ MORE …

The end of a futile quest in management of localized prostate cancer?

Over the years, it has proved almost impossible to recruit patients to comparative trials of different types of first-line treatment in the management of localized prostate cancer — particularly in the USA. … READ MORE …